| Objective To study the effect of total flavonoids combined with salmon calcitonin on elderly patients with chronic obstructive pulmonary disease (COPD) and osteoporosis. Methods Ninety-eight COPD patients with osteoporosis were divided into treatment group (n = 49) and control group (n = 49) according to random number table method. The patients in control group received salmon calcitonin treatment, and the patients in treatment group received the total flavonoids combined with salmon calcitonin for 6 months. After treatment, the levels of serum transforming growth factor-β1 (TGF-β1), interleukin-17 (IL-17), interleukin-17 (IL-17), resistance to tartrate acid phosphatase (TRACP), bone alkaline phosphatase (ALP), bone mineral density of the lumbar spine 1-4 (L1-4) and femoral neck, VAS score, and ODI score were measured. The adverse effects of the patients in two groups were recorded. Results After 6 months of treatment, BMD of L1-4 and femoral neck in the treatment group were significantly higher than those in the control group and before treatment (P<0.05). VAS score and ODI score in the treatment group were significantly lower than those in the control group and before treatment (P<0.05). The levels of TGF-β1 and ALP in the treatment group were significantly higher than those in the control group and before treatment (P<0.05), but the levels of IL-17 and TRACP were significantly lower in the treatment group than those in the control group and before treatment (P<0.05). There was no significant difference in the incidence of adverse drug reactions between the two groups (P>0.05). Conclusion Total flavonoids combined with squid calcitonin can increase bone mineral density, improve bone metabolism and reduce cytokine levels in patients with COPD, and safely and effectively prevent and treat elderly patients with COPD and osteoporosis. |